Table 3. Clinical outcomes and survival rates among patients in the TAH and Bi-HVAD groups.
| Perioperative characteristics | TAH | Bi-HVAD | Overall | P value | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Patients (n/N) | Pooled [95% CI] | I2 (%) | No. of studies | Patients (n/N) | Pooled [95% CI] | I2 (%) | No. of studies | Patients (n/N) | Pooled (95% CI) | I2 (%) | ||||
| Overall mortality (%) | 6 | 94/321 | 36 [22; 49] | 87* | 3 | 10/34 | 26 [6; 46] | 46 | 9 | 104/355 | 33 [22; 45] | 82* | 0.44 | ||
| Mortality on device support (%) | 7 | 129/481 | 26 [17; 36] | 82* | 4 | 10/38 | 21 [4; 37] | 42 | 11 | 139/519 | 25 [17; 33] | 74* | 0.55 | ||
| Death from intracranial hemorrhage (%) | 4 | 7/184 | 3 [1; 7] | 0 | 3 | 3/31 | 10 [3;27] | 0 | 10 | 17/215 | 5[2; 9] | 0 | 0.09 | ||
| Death – multi-organ failure (5) | 5 | 42/238 | 15 [5; 35] | 87* | 1 | 3/13 | 23 [8;52] | NA | 6 | 47/251 | 16 [7; 34] | 83* | <0.01 | ||
| Death sepsis | 5 | 15/195 | 7 [4; 12] | 0 | 2 | 3/16 | 19 [6; 46] | 0 | 7 | 34/211 | 9 [5; 15] | 12 | 0.12 | ||
| Discharge on device (%) | 2 | 7/224 | 6 [4; 17] | 0 | 2 | 13/17 | 73 [48; 89] | 0 | 4 | 20/241 | 33 [6; 78] | 88* | <0.01 | ||
| Heart transplant (%) | 6 | 234/354 | 68 [52; 84] | 92* | 4 | 16/35 | 45 [19; 71] | 67* | 10 | 250/389 | 61 [47; 75] | 90* | 0.14 | ||
| Support duration (days) | 6 | 354 | 71 [15; 127] | 0 | 4 | 31 | 167 [116; 217] | 0 | 10 | 385 | 124 [86; 161] | 0 | 0.01 | ||
| Follow-up time (days) | 6 | 354 | 71 [15; 127] | 0 | 4 | 38 | 159 [109; 209] | 0 | 392 | 120 [83; 157] | 0 | 0.02 | |||
*, heterogeneity P<0.05 (significant data heterogeneity present). TAH, total artificial heart; Bi-HVAD, biventricular HeartWare ventricular assist device.